期刊文献+

对氧磷酶-1与多囊卵巢综合征关系的研究进展

Research progress on relationship between paraoxonase 1 and polycystic ovary syndrome
原文传递
导出
摘要 多囊卵巢综合征(PCOS)是育龄期妇女常见的内分泌代谢紊乱性疾病之一。该病患者常伴肥胖、胰岛素抵抗、糖代谢和脂代谢异常、氧化应激增加、亚临床慢性炎症等,可明显增加代谢综合征、2型糖尿病的发生率以及心血管疾病的发生风险。对氧磷酶(PON)1是高密度脂蛋白(HDL)的重要抗氧化酶之一,具有抗氧化、抗炎症和抗动脉粥样硬化的作用。笔者拟就PON1基因变异、PON1蛋白结构和生理功能以及PON1与PCOS关系的研究进展进行综述如下。 Polycystic ovarian syndrome (PCOS) is one of the most common endocrine metabolic disorders. It is often associated with obesity, insulin resistance, dyslipidemia, increased oxidative stress, systemic low-grade chronic inflammation, elevated prevalenees of metabolic syndrome and type 2 diabetes, and potentially increased the risks of atherosclerosis and cardiovascular disease. Paraoxonase (PON) 1 is one of high-density lipoprotein (HDL)-associated antioxidant enzymes. It possesses antioxidant, anti- inflammatory and anti-atherogenic properties. In this article, we will summarize the research progress on the genetic variations, enzyme activities and physiological functions of PON1 and their relationship to PCOS.
出处 《中华妇幼临床医学杂志(电子版)》 CAS 2015年第2期105-109,共5页 Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
基金 国家自然科学基金项目(81070463 81370681)~~
关键词 多囊卵巢综合征 对氧磷酶1 氧化应激 基因多态性 Polyeystic ovarian syndrome Paraoxonase 1 Oxidative stress Genetic polymorphism
  • 相关文献

参考文献52

  • 1Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in china: a large community-based study[J]. Hum Reprod, 2013, 28(9):2562-Z569.
  • 2The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J]. FertilSteril, 2004, 81(1) :19-25.
  • 3Murri M, Luque-Ramirez M, Insenser M, et al. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS) : a systematic review and meta-analysis[J]. Hum Reprod Update, 2013,19(3) :268-288.
  • 4Zhang J, Fan P, Liu H, et al. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west chinese women with PCOS[J]. Hum Reprod, 2012,27(8):2484-2493.
  • 5Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. Hum Reprod Update, 2012,18(6) : 618-637.
  • 6de Groot PC, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis[,J]. Hum Reprod Update, 2011,17(4): 495-500.
  • 7Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis[,J]. Hum Reprod Update, 2010, 16(4) :347-363.
  • 8Precourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation[J]. Atherosclerosis, 2011,214 ( 1 ) : 20-36.
  • 9Perla-Kajan J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism[J]. Amino acids, 2012, 43(4) : 1405-1417.
  • 10Camps J, Marsiltach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement[J']. Crit Rev Clin Lab Sci, 2009, 46(2) :83-106.

二级参考文献14

  • 1Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci,2009;46(2):83-106.
  • 2Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional layperandrogenism and the polycystic ovary syndrome. Endocr Rev,2005,26(2) :251-282.
  • 3Fenkci IV, Serteser M, Fenkci S, et al. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med, 2007,52(10) : 879-883.
  • 4Dursun P, Demirtas E, Bayrak A, et al. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod, 2006 ; 21 (1) : 104-108.
  • 5San Millan JL, Corton M, Villuendas G, et al. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab, 2004, 89 ( 6 ) : 2640-2646.
  • 6The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polyeystie ovary syndrome. Fertil Steri, 2004 ; 81 ( l ) : 19-25.
  • 7Erlich HA. Principles and applications for DNA amplification. In:Higuchi R. 1st ed. PCR technology. New York: Stockton Press,1989:36.
  • 8Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet,2001 ;68(6) :1428-1436.
  • 9Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond), 2008332(7) : 1035-1041.
  • 10Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med, 2008 ; 26 ( 1 ) : 39-44.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部